Antibiotics act as a safety net for all of healthcare. They make medical procedures such as surgeries, childbirth and cancer treatments possible, but what happens when bacteria or other microorganisms become resistant to the drugs we use against them? 

Back Bay Life Science Advisors’ Managing Director Peter Bak sits down with Marc Lemonnier, a molecular and cellular microbiologist and CEO of Antabio, a clinical stage company located in France developing novel antibiotic therapies, for a conversation on the current clinical landscape of novel agents to address antimicrobial resistance and the regional and global initiatives to tackle the issue. 

Topics include: 

• The growing rates of antimicrobial resistance (AMR) 
• Which global organizations are at work on this issue and their list of priority pathogens a/k/a the world’s “most wanted deadly super bugs”?
• How COVID 19 and the pandemic exacerbated the issue of AMR 
• Push and pull incentives and subscription models for innovative antimicrobials and how they work in various countries around the world
• Why global access is a real issue and how to solve the problem 

For more, read Back Bay Life Science Advisors' recent take on the role of investments in antimicrobials in STAT here. 

Learn more about Antabio, a private biopharmaceutical company developing novel antibacterials targeting drug-resistant pathogens that are deemed a critical priority by the WHO. www.antabio.com

Make sure to subscribe to The Life Science Report podcast and follow Back Bay Life Science Advisors on LinkedIn and Twitter. Thank you for joining us.